Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
But the right medication depends on safety, side effects, coverage, dose tolerance, and the patients long-term plan
The compound is currently in Phase 3 evaluation under the TRIUMPH program, which spans registrational trials in obesity, obstructive sleep apnea, and knee osteoarthritis (PMID 41090431)
And insurance providers may not cover the cost of off-label medications
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review
Currently, Long-Acting GLP-1 Agonists Occupies the Largest Share of the GLP-1 Market In terms of the type of GLP-1 agonists drugs, the market is segmented into short-acting GLP-1 agonist and long-acting GLP-1 agonist
We do not accept responsibility for errors, omissions, changes to product formulations, changes to company policies, or outcomes resulting from the use of the information provided
![UPDATE [March 7, 2025]: OFA takes tirzepatide case to appeals court as legal battle evolves](https://static.wixstatic.com/media/60489a_95b142b425f4416b99f8a052fde88da7~mv2.jpg/v1/fill/w_980,h_551,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/60489a_95b142b425f4416b99f8a052fde88da7~mv2.jpg)
